Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies

More than 2000 immuno-oncology agents are being tested or are in use as a result of the cancer immunotherapy revolution. Manipulation of co-inhibitory receptors has achieved tumor eradication in a minority of patients, but widespread immune-related adverse events (irAEs) compromised tolerance to hea...

Descripción completa

Detalles Bibliográficos
Autores principales: Kerepesi, Csaba, Bakacs, Tibor, Moss, Ralph W., Slavin, Shimon, Anderson, Colin C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183506/
https://www.ncbi.nlm.nih.gov/pubmed/32152702
http://dx.doi.org/10.1007/s00262-020-02543-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183506/
https://www.ncbi.nlm.nih.gov/pubmed/32152702
http://dx.doi.org/10.1007/s00262-020-02543-6

Ejemplares similares